Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy Now?

Is GILD a bully banal to buy? We came crossed a bullish thesis on Gilead Sciences, Inc. connected r/investing_discussion by Variant_Invest. In this article, we volition summarize the bulls’ thesis connected GILD. Gilead Sciences, Inc.'s stock was trading astatine $133.73 arsenic of May 26^th. GILD’s trailing and guardant P/E were 18.19 and 15.22 respectively according to Yahoo Finance.

Pressmaster/Shutterstock.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines successful the areas of unmet aesculapian request successful the United States and internationally. GILD is being mischaracterized by the marketplace arsenic a slow-growth HIV currency cattle contempt a rapidly shifting pipeline that progressively skews toward long-acting HIV innovation and a credible oncology expansion, suggesting the existent valuation underappreciates its multi-platform net durability.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The HIV franchise is not successful structural diminution but is transitioning done lenacapavir, a twice-yearly injectable for attraction and prevention, with PURPOSE 1 and PURPOSE 2 trials demonstrating 100% and 96% efficacy, positioning it arsenic a imaginable paradigm displacement successful adherence and prevention economics. Oncology provides the 2nd pillar with Trodelvy showing traction successful triple-negative bosom crab and further bladder crab expansion, portion broader pipeline assets, contempt anterior setbacks similar magrolimab, inactive make meaningful optionality that is presently priced adjacent zero by the market.

With implicit 17 cardinal dollars successful operating currency travel and a fortress equilibrium sheet, Gilead tin money long-duration pipeline improvement without fiscal strain, supporting sustained R&D concern portion maintaining a 3.5% dividend output that anchors downside risk. At 10–11x guardant earnings, the banal trades astatine a discount to emblematic pharmaceutical peers and adjacent utility-like companies, implying the marketplace is not pricing successful palmy execution of either HIV innovation oregon oncology optionality.

If either lenacapavir adoption accelerates oregon oncology assets execute commercialized success, rerating imaginable becomes important fixed the existent compressed aggregate and resilient currency procreation base. Overall, the setup reflects asymmetric upside with constricted downside fixed currency flows, portion statement underestimates the velocity and magnitude of the HIV modulation and oncology monetization trajectory implicit clip materially.

Previously, we covered a bullish thesis connected Gilead Sciences, Inc. (GILD) by Disruptive analytics successful February 2025, which highlighted near-term gross headwinds from policy, FX, and COVID normalization limiting upside contempt outgo discipline. GILD’s banal terms has appreciated by astir 28.48% since our coverage. Variant_Invest shares a akin presumption but emphasizes pipeline-driven re-rating from lenacapavir and oncology optionalities growth.